MLchartDataset catalogue

Kisqali

Term · Oncology and biomedicine · MLC-T-ONC-004650

A drug used with an aromatase inhibitor or fulvestrant (a type of hormone therapy) to treat adults with certain types of hormone-receptor positive, HER2-negative breast cancer. It is also being studied in the treatment of other types of cancer. Kisqali blocks certain proteins, which may help keep cancer cells from growing. It is a type of cyclin-dependent kinase inhibitor. Also called ribociclib succinate.

Table 1. Record
IdentifierMLC-T-ONC-004650
FieldOncology and biomedicine
Synonymsribociclib succinate
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-004650",
  "term": "Kisqali",
  "field": "Oncology and biomedicine",
  "definition": "A drug used with an aromatase inhibitor or fulvestrant (a type of hormone therapy) to treat adults with certain types of hormone-receptor positive, HER2-negative breast cancer. It is also being studied in the treatment of other types of cancer. Kisqali blocks certain proteins, which may help keep cancer cells from growing. It is a type of cyclin-dependent kinase inhibitor. Also called ribociclib succinate.",
  "synonyms": [
    "ribociclib succinate"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/kisqali/"
}

Record 9,786 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.